BibTeX
CSL-JSON
MLA
Harvard
BRCA1 promoter methylation is linked to defective homologous recombination repair and elevated miR-155 to disrupt myeloid differentiation in myeloid malignancies
release_nag2lvx64zhkhl4v7axzy7qglm
by
Weijie Poh,
Robert Dilley,
Alison Moliterno,
Jaroslaw P Maciejewski,
Keith W. Pratz,
Michael A McDevitt,
James G Herman
Published
in Clinical Cancer Research
by American Association for Cancer Research (AACR).
2019 Volume 25, Issue 8, clincanres.0179.2018
Abstract
Defective homologous recombination (HR) has been reported in multiple myeloid disorders, suggesting a shared dysregulated pathway in these diverse malignancies. Because targeting HR-defective cancers with PARP inhibition (PARPi) has yielded clinical benefit, improved understanding of HR defects is needed to implement this treatment modality.
In text/plain format
Archived Files and Locations
application/pdf
3.1 MB
file_x5tcmqzw2rctfoe7tfwyach6ou
| |
application/pdf
809.4 kB
file_g4izcnrrmfejth6ovdk6od5kmy
|
clincancerres.aacrjournals.org (web) web.archive.org (webarchive) |
application/pdf
3.1 MB
file_zssguuksmng4tng2o3lklug7ie
|
clincancerres.aacrjournals.org (web) web.archive.org (webarchive) |
Read Archived PDF
Preserved and Accessible
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
access all versions, variants, and formats of this works (eg, pre-prints)
Cite This
Lookup Links
oaDOI/unpaywall (OA fulltext)
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar
Crossref Metadata (via API)
Worldcat
SHERPA/RoMEO (journal policies)
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar